{"component": "definition", "props": {"groups": [{"samples": [{"hash": "kHxGeIkrcLw", "uri": "https://www.govinfo.gov/content/pkg/BILLS-111hr5440ih/pdf/BILLS-111hr5440ih.pdf", "label": "www.govinfo.gov", "score": 5.2094455852, "published": false}, {"hash": "e8RvDDErZhN", "uri": "https://www.congress.gov/111/bills/hr5440/BILLS-111hr5440ih.pdf", "label": "www.congress.gov", "score": 5.2094455852, "published": false}], "size": 2, "snippet_links": [{"key": "the-study", "type": "definition", "offset": [8, 17]}], "snippet": "\u2019 means the study of indi-", "hash": "38ab6f55bea5751b4c8cc0e3a16ab40b", "id": 1}, {"samples": [{"hash": "9KbLh5TcIhn", "uri": "/contracts/9KbLh5TcIhn#pharmacogenomics", "label": "Distributor Agreement (Dna Sciences Inc)", "score": 18.0, "published": true}, {"hash": "3AYf4ZFhly1", "uri": "/contracts/3AYf4ZFhly1#pharmacogenomics", "label": "Agreement and Plan of Merger and Reorganization (Axys Pharmecueticals Inc)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "same-meaning", "type": "clause", "offset": [15, 27]}, {"key": "executed-by", "type": "definition", "offset": [87, 98]}, {"key": "the-corporation", "type": "clause", "offset": [142, 157]}], "snippet": "shall have the same meaning set forth in the Technology Transfer and License Agreement executed by and between Axys Pharmaceuticals, Inc. and the Corporation effective as of February 1, 1999.", "hash": "978fc848d43ef3cf712b4a8a8cec0fb9", "id": 2}, {"samples": [{"hash": "gieMjv75dvj", "uri": "https://www.rrfa.co.za/wp-content/uploads/2020/07/NDA-Final-version_Biotherapeutic-Guidelines-19-10-14.pdf", "label": "www.rrfa.co.za", "score": 9.8856947296, "published": false}, {"hash": "1BLkSW8o8ja", "uri": "https://pink.pharmaintelligence.informa.com/-/media/supporting-documents/pink-sheet/2023/03/p0323uga_3.pdf", "label": "pink.pharmaintelligence.informa.com", "score": 9.5681040383, "published": false}], "size": 2, "snippet_links": [{"key": "the-study", "type": "definition", "offset": [6, 15]}, {"key": "drug-development", "type": "clause", "offset": [148, 164]}, {"key": "the-risk", "type": "definition", "offset": [202, 210]}, {"key": "adverse-drug-reactions", "type": "clause", "offset": [225, 247]}, {"key": "the-response", "type": "clause", "offset": [262, 274]}], "snippet": "means the study of the pharmacological correlation between drug response and variations in genetic elements has become of increasing importance for drug development. Such variations can have effects on the risk of developing adverse drug reactions as well as on the response to treatment. Variations in drug pharmacokinetics and metabolic pathways can cause higher drug concentrations in some patients, resulting in increased drug toxicity, and/or lower drug concentrations in some patients, resulting in decreased drug effects.", "hash": "8213c916e530d16566c9f1d4d4a57f03", "id": 3}, {"samples": [{"hash": "fbX2FnFmii4", "uri": "/contracts/fbX2FnFmii4#pharmacogenomics", "label": "Rights Exchange Agreement (Millennium Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "aOtVjGevE3c", "uri": "/contracts/aOtVjGevE3c#pharmacogenomics", "label": "Technology Transfer and License Agreement (Millennium Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "based-on", "type": "clause", "offset": [23, 31]}, {"key": "human-tissue", "type": "definition", "offset": [58, 70]}, {"key": "without-limitation", "type": "clause", "offset": [83, 101]}, {"key": "cell-lines", "type": "definition", "offset": [103, 113]}, {"key": "the-safety", "type": "clause", "offset": [188, 198]}], "snippet": "means the correlation, based on analysis of animal and/or human tissue (including, without limitation, cell lines), of a biological marker (e.g., DNA, RNA or protein) with measurements of the safety and/or efficacy of a preventative and/or therapeutic substance or candidate.", "hash": "c16afb60ada66140c0206e22bfdedb67", "id": 4}, {"samples": [{"hash": "3cTNorlFo3d", "uri": "/contracts/3cTNorlFo3d#pharmacogenomics", "label": "License Agreement (Cytogenix Inc)", "score": 18.0, "published": true}], "size": 1, "snippet_links": [{"key": "related-to", "type": "clause", "offset": [18, 28]}, {"key": "the-individual", "type": "clause", "offset": [109, 123]}], "snippet": "means the science related to the identification and elucidation of genetic variations that correlate with an the individual's response and reaction to specific drugs and using specific nucleotide sequences to alter expression of selected genes to achieve a therapeutic result.", "hash": "3460fabb2e822e7f864f9364a49071c5", "id": 5}, {"samples": [{"hash": "3AYf4ZFhly1", "uri": "/contracts/3AYf4ZFhly1#pharmacogenomics", "label": "Agreement and Plan of Merger and Reorganization (Axys Pharmecueticals Inc)", "score": 18.0, "published": true}], "size": 1, "snippet_links": [{"key": "related-information", "type": "definition", "offset": [58, 77]}, {"key": "an-individual", "type": "clause", "offset": [106, 119]}, {"key": "the-safety", "type": "clause", "offset": [147, 157]}, {"key": "development-program", "type": "definition", "offset": [236, 255]}, {"key": "diagnosis-and-treatment", "type": "definition", "offset": [286, 309]}, {"key": "to-determine", "type": "clause", "offset": [327, 339]}, {"key": "disposition-of", "type": "clause", "offset": [373, 387]}, {"key": "by-way-of-illustration", "type": "clause", "offset": [457, 479]}, {"key": "development-of", "type": "clause", "offset": [649, 663]}, {"key": "in-connection-with", "type": "clause", "offset": [703, 721]}, {"key": "clinical-diagnostics", "type": "definition", "offset": [763, 783]}, {"key": "based-on", "type": "clause", "offset": [854, 862]}, {"key": "the-development", "type": "clause", "offset": [919, 934]}], "snippet": "or \"PGX\" means the gathering and use of genetic and other related information, whether from a population, an individual or animals, to (i) predict the safety, toxicity and/or efficacy of drugs for humans as part of a drug discovery and development program or as part of an individual's diagnosis and treatment regimen; or (ii) to determine or predict the susceptibility or disposition of an individual to disease, disease complications, and disease course. By way of illustration and not limitation, \"Pharmacogenomics\" includes identification of candidate genes and polymorphisms, correlation of polymorphisms to clinical outcomes and drug effects, development of novel algorithms and informatics tools in connection with such identification and correlation, and clinical diagnostics, such as prediction of drug response or selection and dosing of drugs based on genotype and/or expression, i.e., phenotype, as well as the development of genetic tests or screens for use in predicting susceptibility to disease, disease complications and disease course.", "hash": "d9026722ad8f15a6eba1e0c58973cb9d", "id": 6}, {"samples": [{"hash": "aQos0PP706B", "uri": "https://cdn.ymaws.com/www.nursepractitionersoforegon.org/resource/resmgr/Docs/OSBN_BdMtgPublicPacket_11-14.pdf", "label": "cdn.ymaws.com", "score": 11.5612594114, "published": false}], "size": 1, "snippet_links": [{"key": "the-study", "type": "definition", "offset": [6, 15]}, {"key": "relationship-between", "type": "clause", "offset": [23, 43]}, {"key": "specific-person", "type": "definition", "offset": [46, 61]}], "snippet": "means the study of the relationship between a specific person's", "hash": "0ad4c7d9c5b91c06e2f6e67a81101b11", "id": 7}, {"samples": [{"hash": "19LIlxE4bs2", "uri": "/contracts/19LIlxE4bs2#pharmacogenomics", "label": "Software License Agreement (Pharmaceutical Product Development Inc)", "score": 18.0, "published": true}], "size": 1, "snippet_links": [{"key": "executed-by", "type": "definition", "offset": [82, 93]}, {"key": "on-february", "type": "clause", "offset": [148, 159]}], "snippet": "shall have the meaning set forth in the Technology Transfer and License Agreement executed by and between Axys Pharmaceuticals, Inc. and PPGx, Inc. on February 1, 1999.", "hash": "5f0bb9b7b66fb884bb670e3af9e3705d", "id": 8}, {"samples": [{"hash": "8BF8DLtbBJQ", "uri": "https://trackbill.com/s3/bills/CA/2023/AB/425/analyses/assembly-health.pdf", "label": "trackbill.com", "score": 9.6119096509, "published": false}], "size": 1, "snippet_links": [{"key": "the-evaluation", "type": "clause", "offset": [6, 20]}, {"key": "a-person", "type": "clause", "offset": [28, 36]}, {"key": "selection-of", "type": "definition", "offset": [121, 133]}, {"key": "adverse-drug-events", "type": "clause", "offset": [185, 204]}], "snippet": "means the evaluation of how a person\u2019s genes affect how the person responds to medications. Pharmacogenomics enables the selection of drugs and doses best suited to reduce toxicity and adverse drug events, including treatment failures, severe harm, or even death;", "hash": "4bb6c94979c59f69987529b8da4ae4e7", "id": 9}, {"samples": [{"hash": "3AYf4ZFhly1", "uri": "/contracts/3AYf4ZFhly1#pharmacogenomics", "label": "Agreement and Plan of Merger and Reorganization (Axys Pharmecueticals Inc)", "score": 18.0, "published": true}], "size": 1, "snippet_links": [{"key": "the-safety", "type": "clause", "offset": [61, 71]}, {"key": "development-program", "type": "definition", "offset": [150, 169]}, {"key": "an-individual", "type": "clause", "offset": [184, 197]}, {"key": "diagnosis-and-treatment", "type": "definition", "offset": [200, 223]}, {"key": "but-excluding", "type": "clause", "offset": [232, 245]}], "snippet": "means compositions, assays and methods useful for predicting the safety, toxicity and/or efficacy of drugs for humans as part of a drug discovery and development program or as part of an individual's diagnosis and treatment regimen but excluding predicting modes of function of a therapeutic.", "hash": "015e4079a8e66f851c9a8a5ed3ab5940", "id": 10}], "next_curs": "Cl0SV2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjkLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIZcGhhcm1hY29nZW5vbWljcyMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Pharmacogenomics", "size": 13, "snippet": "\u2019 means the study of indi-", "id": "pharmacogenomics", "examples": ["Designated Products&quot; are all existing and future <strong>Pharmacogenomics</strong> software programs, documentation, information and information systems, sequences, sample collections, technology and methods, including Enhancements, developed or licensed by the Corporation and which the Corporation makes available for sale or licensing, as the case may be, from time to time.", "In 2011, the Clinical <strong>Pharmacogenomics</strong> Implementation Consortium (CPIC) was founded [3].", "Designated Services&quot; are all existing and future <strong>Pharmacogenomics</strong> contract, consulting, research and development, laboratory, and technical and maintenance support services, including Enhancements (as hereinafter defined), offered by or available to the Corporation from time to time.", "The latter contain nearly all variants from the DMET and Illumina ADME core panel, in addition to all genes and variants with clinical annotations in CPIC and PharmGKB (<strong>Pharmacogenomics</strong> knowledge base), HLA genes and sample ID and tracking markers.", "Each Party will attempt to accommodate any reasonable request of the other Party to send or receive personnel for purposes of collaborating or exchanging information under the <strong>Pharmacogenomics</strong> Program.", "Medical education in <strong>pharmacogenomics</strong>-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European <strong>pharmacogenomics</strong> clinical implementation project Ubiquitous <strong>Pharmacogenomics</strong> (U-PGx).", "<strong>Pharmacogenomics</strong>&quot; shall have the same meaning set forth in the Technology Transfer and License Agreement executed by and between Axys Pharmaceuticals, Inc.", "Subject to the general limitations of Section 4.01 and to the terms, limitations, conditions and agreements contained herein, Tenant may use the Demised Premises for the following purposes but for none other without Landlord\u2019s prior written consent: General offices, administration, research and development, product packaging, storage and shipping for a <strong>Pharmacogenomics</strong> company.", "In addition, each Party agrees to carry out all work done in the course of the <strong>Pharmacogenomics</strong> Program in material compliance with all applicable federal, state or local laws, regulations and guidelines governing the conduct of such work, including, without limitation, all applicable export and import control laws.", "BAYER and CURAGEN <strong>Pharmacogenomics</strong> Project Agreement as necessary to carry out the <strong>Pharmacogenomics</strong> Program."], "related": [["bioassay", "Bioassay", "Bioassay"], ["clinical", "Clinical", "Clinical"], ["medical-cannabis-pharmacy", "Medical cannabis pharmacy", "Medical cannabis pharmacy"], ["commercialization", "Commercialization", "Commercialization"], ["biomarker", "Biomarker", "Biomarker"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}